BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 19343301)

  • 1. Imatinib in the treatment of solid tumours.
    Duffaud F; Le Cesne A
    Target Oncol; 2009 Jan; 4(1):45-56. PubMed ID: 19343301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular research directions in the management of gastrointestinal stromal tumors.
    Tarn C; Godwin AK
    Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development and application of imatinib.
    Jones RL; Judson IR
    Expert Opin Drug Saf; 2005 Mar; 4(2):183-91. PubMed ID: 15794712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New oncological treatment principle with imatinib].
    Kuenen BC; Pinedo HM
    Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Imatinib and solid tumours].
    Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
    Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal stromal tumors.
    Antonescu C
    Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular pathogenesis of gastrointestinal stromal tumors.
    Tarn C; Godwin AK
    Clin Colorectal Cancer; 2006 Nov; 6 Suppl 1():S7-17. PubMed ID: 17101067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
    Liu Y; Tseng M; Perdreau SA; Rossi F; Antonescu C; Besmer P; Fletcher JA; Duensing S; Duensing A
    Cancer Res; 2007 Mar; 67(6):2685-92. PubMed ID: 17363589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
    Burger H; den Bakker MA; Kros JM; van Tol H; de Bruin AM; Oosterhuis W; van den Ingh HF; van der Harst E; de Schipper HP; Wiemer EA; Nooter K
    Cancer Biol Ther; 2005 Nov; 4(11):1270-4. PubMed ID: 16294026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
    Deininger MW
    J Cancer Res Clin Oncol; 2004 Feb; 130(2):59-72. PubMed ID: 14605878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib treatment for gastrointestinal stromal tumour (GIST).
    Lopes LF; Bacchi CE
    J Cell Mol Med; 2010 Jan; 14(1-2):42-50. PubMed ID: 19968734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Imatinib . Sunitinib].
    Nishida T
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1196-200. PubMed ID: 17687201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib resistance in gastrointestinal stromal tumors.
    Chen LL; Sabripour M; Andtbacka RH; Patel SR; Feig BW; Macapinlac HA; Choi H; Wu EF; Frazier ML; Benjamin RS
    Curr Oncol Rep; 2005 Jul; 7(4):293-9. PubMed ID: 15946589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia in two patients with gastrointestinal stromal tumor.
    Sakamoto E; Sawada T; Osugi H; Nakamae H; Koh KR; Yamane T; Ohsawa M; Wakasa K; Hino M
    Int J Hematol; 2008 Oct; 88(3):348-350. PubMed ID: 18758897
    [No Abstract]   [Full Text] [Related]  

  • 16. Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.
    Kim TS; Cavnar MJ; Cohen NA; Sorenson EC; Greer JB; Seifert AM; Crawley MH; Green BL; Popow R; Pillarsetty N; Veach DR; Ku AT; Rossi F; Besmer P; Antonescu CR; Zeng S; Dematteo RP
    Clin Cancer Res; 2014 May; 20(9):2350-62. PubMed ID: 24583793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.
    Koseła-Paterczyk H; Rutkowski P
    Expert Rev Anticancer Ther; 2017 Dec; 17(12):1107-1116. PubMed ID: 28988501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate in the treatment of gastrointestinal stromal tumour.
    Steinert DM; McAuliffe JC; Trent JC
    Expert Opin Pharmacother; 2005 Jan; 6(1):105-13. PubMed ID: 15709888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor.
    Sawyers CL
    J Clin Oncol; 2002 Sep; 20(17):3568-9. PubMed ID: 12202652
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib.
    Murray M; Hatcher H; Jessop F; Williams D; Carroll N; Bulusu R; Judson I
    Pediatr Blood Cancer; 2008 Feb; 50(2):386-8. PubMed ID: 17729245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.